T2 Biosystems Announces Issuance of Patents Covering T2MR Direct Detection Technology

T2 Biosystems Announces Issuance of Patents Covering T2MR Direct Detection Technology

November 14, 2012

LEXINGTON, Mass., Nov 14, 2012 (BUSINESS WIRE) -- T2 Biosystems, a company developing direct detection products enabling superior diagnostics, today announced the U.S. Patent and Trademark Office has issued two patents adding depth and breadth to the Company's intellectual property portfolio. These patents cover both the device and methods related to the Company's flagship T2Candida assay and the detection of additional biological analytes, including specific drug and biomarker targets, in biological samples using the T2MR platform.

"These patents illustrate the success that T2 Biosystems' team has had in its mission to create breakthrough diagnostic detection technology that will enable the first direct detection of analytes in biological samples," said John McDonough, President and CEO, T2 Biosystems. "Direct detection provides many advantages, including industry-leading clinical performance and the ability to run molecular, immuno and hemostasis assays on a single platform. This intellectual property covers the proprietary methods for our lead product, the T2Candida assay. Importantly, though, it extends the coverage to additional key aspects of our T2MR-based platform: detection of multiple analytes associated with disease, therapeutic management and monitoring a patient's response to medical intervention."

In Patent Number 8,310,231, "NMR device for detection of analytes", the claims are specific to T2MR, the core of the T2Dx system. The claims broadly describe the configurations of T2MR to detect analyte-mediated aggregation of magnetic particles in the sample.

In Patent Number 8,310,232, "NMR device for the detection of analytes", the claims cover the use of a removable cartridge containing the reagents required to conduct the T2Candida diagnostic assay as well as other assays currently under development. The claims further describe configurations of the assays to detect analyte-mediated aggregation of magnetic particles in a sample.

About T2 Biosystems

T2 Biosystems is disrupting the landscape of clinical diagnostics with T2MR, the Company's proprietary magnetic biosensor detector. The T2MR technology enables healthcare professionals to save lives and reduce costs by providing sensitive, accurate and rapid assay results. The Company's products detect molecular, hemostasis or immunoassay targets directly from unpurified clinical samples in hospitals, labs and physicians' offices. For more information, please visit www.t2biosystems.com .

 

SOURCE: T2 Biosystems


        
        MacDougall Biomedical Communications 
        Chris Erdman, 781-235-3060 
        cerdman@macbiocom.com